- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Symptom Checklist 90.
Displaying page 1 of 1.
EudraCT Number: 2020-005956-39 | Sponsor Protocol Number: RC31/18/0471 | Start Date*: 2021-04-06 | |||||||||||
Sponsor Name:CHU Toulouse | |||||||||||||
Full Title: Treatment of pediatric Post-traumatic Stress Disorder with memory reactivation under the influence of propranolol: A randomized placebo-controlled trial | |||||||||||||
Medical condition: Post-traumatic Stress Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004739-19 | Sponsor Protocol Number: OSU6162aSAH | Start Date*: 2017-06-16 |
Sponsor Name:Oslo University Hospital | ||
Full Title: OSU6162 IN THE TREATMENT OF FATIGUE AND OTHER NEUROPSYCHOLOGICAL SEQUELAE AFTER ANEURYSMAL SUBARACHNOIDAL HEMORRHAGE - A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY | ||
Medical condition: Fatigue and neuropsychological dysfunction after aneurysmal brain hemorrhage | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018740-13 | Sponsor Protocol Number: acareoxt01 | Start Date*: 2011-08-25 | ||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||
Full Title: Short- and long-term effects of oxytocin on empathy and social behaviour in autistic and antisocial male adults. | ||||||||||||||||||
Medical condition: Antisocial personality disorder Autism spectrum disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005592-17 | Sponsor Protocol Number: P05059 | Start Date*: 2006-12-14 | |||||||||||
Sponsor Name:Schering-Plough AB Sweden | |||||||||||||
Full Title: Caelyx® in Breast Cancer in the Elderly Pegylated Liposomal Doxorubicin (Caelyx®) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer | |||||||||||||
Medical condition: Locally advanced and/or metastatic breast cancer, not amenable to surgery. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017838-44 | Sponsor Protocol Number: CJO-201 | Start Date*: 2010-04-21 | |||||||||||
Sponsor Name:Sequel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003791-13 | Sponsor Protocol Number: BP42992 | Start Date*: 2022-01-11 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15... | |||||||||||||
Medical condition: Dup15q Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000643-25 | Sponsor Protocol Number: 205520003 | Start Date*: 2011-04-19 | ||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
Full Title: The Qure study: Q-fever fatigue syndrome - response to treatment | ||||||||||||||||||
Medical condition: Q fever fatigue syndrome (QFS) is one of the most frequent sequelae of Q fever. QFS leads to substantial morbidity, a high socio-economic burden and an increased use of healthcare facilities. QFS: ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002489-34 | Sponsor Protocol Number: AV-APL-B-002-22 | Start Date*: 2023-02-09 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromi... | |||||||||||||
Medical condition: Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001807-19 | Sponsor Protocol Number: TV50717-CNS-30081 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) | |||||||||||||
Medical condition: Dyskinesia in cerebral palsy (DCP) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005331-23 | Sponsor Protocol Number: SCOUT-015 | Start Date*: 2022-06-20 | |||||||||||
Sponsor Name:Radius Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome | |||||||||||||
Medical condition: Hyperphagia related behavior associated with Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
